MicroRNA-221 participates in cerebral ischemic stroke by modulating endothelial cell function by regulating the PTEN/PI3K/AKT pathway

HAN PENG1,2, HUA YANG2, XIN XIANG2 and SHENGGANG LI2

1Department of Pathology, Guizhou Medical University, Guiyang, Guizhou 550025; 2Department of Neurosurgery, Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou 550002, P.R. China

Received February 19, 2019; Accepted June 27, 2019

DOI: 10.3892/etm.2019.8263

Abstract. An effective method to improve the blood supply of brain tissue is by angiogenesis, which is crucial for the prognosis of patients with cerebral ischemic stroke (CIS). Therefore, angiogenesis has been a focus of CIS research in recent years. The present study aimed to investigate the expression of microRNA (miR)-221 in patients with CIS and to explore the effect of miR-221 on endothelial cell function. The level of miR-221 was detected using reverse transcription-quantitative PCR (RT-qPCR). The relationship between miR-221 and phosphatase and tensin homolog (PTEN) was predicted and confirmed by bioinformatics and dual luciferase reporter assay. Cell viability, migration and invasion, and cell apoptosis were determined using MTT assay, Transwell assay and flow cytometry respectively. Tube formation in human umbilical vein endothelial cells (HUVECs) was determined by performing the tube formation assay. In addition, protein levels were measured using western blot analysis. The results of the current study indicated that miR-221 levels were significantly decreased in the peripheral blood of patients with CIS. PTEN was confirmed to be a direct target of miR‑221. Downregulation of miR-221 significantly inhibited the function of HUVECs as evidenced by the decreased cell viability, migration and invasion with increased cell apoptosis and tube formation inhibition. miR-221 upregulation produced the reverse effects, whilst all the effects of miR-221 upregulation on HUVECs were reversed by PTEN overexpression. The PI3K/AKT pathway was identified to be involved in the regulation of miR-221 on HUVECs. In conclusion, miR-221 was downregulated in CIS patients, and it promoted the function of HUVECs by regulating the PTEN/PI3K/AKT pathway in vitro, suggesting the ability to promote angiogenesis. Therefore, miR-221 may be a novel and promising therapeutic target for CIS treatment.

Introduction

Cerebral ischemic stroke (CIS), a cerebrovascular disease with high incidence, disability rate and recurrence rate, seriously endangers human life and health accounting for 60-80% of all strokes (1,2). CIS imposes a burden on the patient's family and society (3). Therefore, in order to promote the recovery of nerve function, reduce the disability rate and improve the prognosis of CIS patients it is of great significance to explore new treatment methods for CIS.

Numerous studies have demonstrated that new blood vessels improve the blood supply of local brain tissue thereby providing nutritional support for neurons, saving sudden death neurons and improving the prognosis of CIS patients (4-6). Therefore, timely and effective promotion of neovascularization in the cerebral ischemic area has an important role in the recovery of neurological function of ischemic brain tissue. As an effective method to improve the blood supply of brain tissue, angiogenesis is crucial for the prognosis of patients with CIS (7-9) therefore has been the focus of CIS research in recent years. Angiogenesis refers to the proliferation, migration and remodeling of endothelial cells from original blood vessels as well as the formation of new blood vessels by budding to meet the biological function of local tissues (10). Angiogenesis serves an important role in various physiological and pathological processes such as wound healing, tissue regeneration, tumorigenesis and ischemia (11,12). Angiogenesis is a critical process of recovery from cerebrovascular disease (8,9).

MicroRNAs (miRNAs), a group of small non-coding RNAs, can regulate gene expression through binding to the 3'-untranslated regions (3'-UTRs) of the target mRNAs, and have key roles in the regulation of cell proliferation, differentiation and apoptosis (13,14). Currently, miRNAs have been identified as crucial regulatory factors that may serve as diagnostic biomarkers and/or therapeutic targets for human diseases. A large body of evidence indicates that miRNAs have important regulatory roles in angiogenesis (15-17). Increasing amounts of studies have demonstrated that miRNAs can participate in
the development of CIS by regulating angiogenesis (18-20). miR-221 has been well studied in a variety of cancers (21-24) and has also been identified to be downregulated in CIS patients (25,26). However, to the best of our knowledge, the role and mechanism of miR-221 in CIS remains unclear.

In the present study, the expression pattern of miR-221 in the plasma of patients with CIS was investigated and *in vitro* experiments explored the effects and mechanisms of miR-221 on the function of human umbilical vein endothelial cells (HUVECs). Findings will hopefully provide a potential new target for the treatment of CIS.

**Materials and methods**

**Clinical samples.** A total of 20 samples of peripheral blood from 20 patients with CIS (13 males and 7 females; age range, 35 to 67 years) and 20 samples of peripheral blood from 20 healthy volunteers without any cerebrovascular diseases (12 males and 8 females; age range, 33 to 71 years) were collected at The Affiliated Hospital of Guizhou Medical University (Guizhou, China) from May 2016 to June 2018. Blood samples were centrifuged at 1,000 x g for 10 min at 4˚C to obtain serum. The diagnosis of CIS was confirmed by computed tomography scan (CT) or magnetic resonance imaging scan (MRI) examinations. Inclusion criteria were as follows: i) Presentation of symptoms within 72 h of the event; ii) National Institutes of Health Stroke Scale (NIHSS) score between 4 and 15 (27); and iii) Apache II score equal to or below 22, Cincinnati Score positive (28) for neurological symptoms at admission (including dysarthria and hemiparesis) and neuroimaging positive (CT or MRI positive). Exclusion criteria were patients with severe renal, liver, or thyroid failure, acute infectious disease, rheumatic immune or hematologic disease, cancer, or they had been taking lipid-lowering drugs within the last half of the year. The present study was approved by The Ethical Committee of the Affiliated Hospital of Guizhou Medical University and written informed consent was obtained from each patient.

**Cell culture.** Human umbilical vein endothelial cells (HUVECs) were purchased from American Type Culture Collection. HUVECs were grown in DMEM (Invitrogen; Thermo Fisher Scientific, Inc.) containing 10% FBS (HyClone; GE Healthcare Life Sciences) and the cells were incubated at 37˚C and 5% CO₂.

**Cell transfection.** HUVECs were transfected with 100 nM inhibitor (5'-CAGUACUUUUGUGUAGUACAA-3'; Shanghai GenePharma Co., Ltd.), 100 nM miR-221 inhibitor (5'-GAA ACCCGCAGACAUGUAACGU-3'; Shanghai GenePharma Co., Ltd.), 50 nM mimic control (sense, 5'-UUCUCCGAACGUGUCAGU-3' and antisense, 5'-ACGUGA CACGUCUCCGAGATT-3'; Shanghai GenePharma Co., Ltd.), 50 nM miR-221 mimic (sense, 5'-ACGUCAUUGUCUGCGGCUU-3' and antisense, 5'-AACCGAGCAC AAGUACGUUU-3'; Shanghai GenePharma Co., Ltd.), 1 µg control-plasmid (cat. no. sc-437275; Santa Cruz Biotechnology, Inc.), 1 µg phosphatase and tensin homolog (PTEN)-plasmid (cat. no. sc-400103-ACT; Santa Cruz Biotechnology, Inc.), 50 nM miR-221 mimic + 1 µg control-plasmid or 50 nM miR-221 mimic + 1 µg PTEN-plasmid for 48 h using Lipofectamine® 2000 reagent (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol. Transfection efficiency was detected by reverse transcription-quantitative PCR (RT-qPCR) 48-h following transfection.

**Reverse transcription-quantitative PCR (RT-qPCR).** To collect the total RNA from serum and cells, TRIzol® reagent (Invitrogen; Thermo Fisher Scientific, Inc.) was used according to the manufacturer's instructions. The PrimeScript™ RT reagent kit (Takara Bio, Inc.) was used to synthesize cDNAs following the manufacturer's instructions. The temperature protocol for the reverse transcription reaction was as follows: 50˚C for 5 min and 90˚C for 2 min for qPCR. SYBR® Premix Ex Taq (Takara Bio, Inc.) was performed according to the manufacturer's protocol. The primer sequences used were as follows: U6 forward, 5'-GCTTCGCGACACATATACAAA T-3' and reverse, 5'-CGCTTCAGAATTTGCGTGCT-3'; GAPDH forward, 5'-CTTGTGATCTGGAGAGACTC-3' and reverse, 5'-GTAGAGGCAAGGATGATTCT-3'; miR-221 forward, 5'-TGGCAGATCATCATTGTCTGTTG-3' and reverse, 5'-CCATGTCAGGGTCCAGGT-3' and PTEN forward, 5'-GTCACTGTTGTTTGTTCG-3' and reverse, 5'-TTCCCTGTGTATAGCCTCAC-3'. Thermocycling conditions were as follows: 10 min at 95˚C followed by 37 cycles of 15 sec at 95˚C and 40 sec at 55˚C. Relative gene expression was quantified by the 2-∆∆Ct method (29) and normalized to U6 or GAPDH. Each experiment was performed in triplicate.

**Western blot analysis.** Total proteins were extracted from cells using RIPA lysis buffer (Beyotime Institute of Biotechnology) according to the manufacturer's protocol. To quantify the protein samples, a bicinchoninic acid protein quantitative kit (Thermo Fisher Scientific, Inc.) was used, according to the manufacturer's instructions. Then an equal amount of proteins (35 µg/lane) was separated by SDS-PAGE on 10% gels and transferred to polyvinylidene difluoride membranes. Subsequently, the membranes were blocked with 5% non-fat milk at room temperature for 1 h and then incubated with primary antibodies against PTEN (cat. no. 9188; 1:1,000; Cell Signaling Technology, Inc.), Bcl-2 (cat. no. 3498; 1:1,000; Cell Signaling Technology, Inc.), Bax (cat. no. 5023; 1:1,000; Cell Signaling Technology, Inc.), phosphorylated (p) -AKT (cat. no. 4060; 1:1,000; Cell Signaling Technology, Inc.), AKT (cat. no. 4685; 1:1,000; Cell Signaling Technology, Inc.), Bcl-2 (cat. no. 3498; 1:1,000; Cell Signaling Technology, Inc.), and PTEN (cat. no. 9188; 1:1,000; Cell Signaling Technology, Inc.) at 4˚C overnight. Membranes were then incubated with horseradish peroxidase-conjugated secondary antibody anti-rabbit IgG (1:2,000; cat. no. 7074; Cell Signaling Technology, Inc.) at room temperature for 2 h. Protein bands were visualized using an enhanced chemiluminescence kit (EMD Millipore) and the proteins were quantified by densitometry (Quantity One 4.5.0 software; Bio-Rad Laboratories, Inc.) with β-actin as the loading control.

**MTT assay.** Following specific treatments, cell viability was detected by MTT assay. The day before cell transfection, HUVECs were seeded into a 96-well plate (5x10⁴ cells/well) and incubated at 37˚C. Following transfection with or without inhibitor control, miR-221 inhibitor, mimic control, miR-221 mimic, miR-221 mimic + control-plasmid, or miR-221 mimic + PTEN-plasmid for 48-h, 20 µl MTT reagent was added to
each well. Then the cells were incubated at 37°C for a further 4 h following which 150 μl dimethyl sulfoxide (DMSO) was applied in each well to dissolve the purple formazan crystals. Finally, the absorbance was detected at 490 nm wavelength using the FLUOstar® Omega Microplate Reader (BMG Labtech GmbH).

Flow cytometry. Following specific treatments, the apoptosis of HUVECs was analyzed using the Annexin V-fluorescein isothiocyanate (FITC)/propidium iodide (PI) apoptosis detection kit [cat. no.70-AP101-100; Hangzhou MultiSciences (Lianke Biotech Co., Ltd.)] according to the manufacturer's protocol. Briefly, 48 h following cell transfection, HUVECs were collected, washed with PBS, fixed in 70% ethanol at 4°C overnight and then stained with 5 μl Annexin V-FITC and 5 μl PI for 30 min in the dark at room temperature. A flow cytometer (BD FACS Aria; BD Biosciences) was used to analyze cell apoptosis and FlowJo software (version 7.6.1; FlowJo LLC) was used for data analysis. Experiments were repeated at least 3 times.

Transwell assay. In the present study, in vitro invasion and migration assays were performed using Transwell plates (pore size, 8 μm; BD Biosciences) with (invasion assay) or without Matrigel® (migration assay; BD Biosciences). The Matrigel pre-coating procedures were carried out at 37°C for 5 h. HUVECs (1x10⁴ cells) diluted in serum-free DMEM were plated into the upper chamber of the Transwell plates. Then 600 µl DMEM medium containing 20% FBS as the chemoattractant was added to the lower chamber. Following 48-h incubation, cells on the upper surface of the membrane were removed and the invasive or migratory cells on the lower surface of the membrane were fixed with methanol at room temperature for 30 min and then stained with 0.5% crystal violet at room temperature for 20 min. The membrane was counted in five randomly selected visual fields under an inverted light microscope (magnification, x100; Olympus Corporation) using which the mean values were calculated.

Tube formation assay. Endothelial tube formation in HUVECs was determined by performing the tube formation assay. At 48-h following cell transfection, HUVECs (2x10⁴ per well) were plated into the 96-well plates which were first pre-coated with 10 mg/ml Matrigel® at 37°C for 1 h (Becton, Dickinson and Company) and incubated in fully-supplemented DMEM for 24 h. To quantify tube formation, the tube length was calculated using ImageJ 1.38X software (National Institutes of Health).

Dual luciferase reporter assay. To predict the potential targets of miR-221, microRNA target site prediction software (www.microrna.org; August 2010 Release) was used. The binding sites between the 3'-UTR of PTEN and miR-221 were identified. Then, a dual luciferase reporter assay was performed to confirm the binding sites between the 3'-UTR of PTEN and miR-221. The wild type (WT)-PTEN and mutant (MUT)-PTEN 3'-UTR of PTEN were cloned into a pmiR-RB-Report™ dual luciferase reporter gene plasmid vector (Guangzhou RiboBio Co., Ltd.) according to the manufacturer's protocol. To point-mutate the miR-221 binding domain on the 3'UTR of PTEN, a QuikChange Site-Directed Mutagenesis kit (Stratagene; Agilent Technologies, Inc.) was performed in accordance with the manufacturer's protocol. HUVECs were co-transfected with 1 μg WT-PTEN or 1 μg MUT-PTEN and 50 nM miR-221 mimic or 50 nM mimic control using Lipofectamine® 2000 (Invitrogen; Thermo Fisher Scientific, Inc.) in line with the manufacturer's protocols. Following 48 h incubation, a dual-luciferase assay system (Promega Corporation) was used to assess the luciferase activity. Luciferase activity was normalized to the Renilla luciferase activity.

Statistical analysis. Experiments were repeated for three times. SPSS 18.0 (SPSS, Inc.) was used to perform statistical analyses. Data are presented as the mean ± standard deviation. Comparison between two groups was made using Student's t-test or between multiple groups using one-way analysis of variance with Tukey's post hoc test. P<0.05 was considered to indicate statistical significance.

Results

miR-221 is significantly downregulated in the blood of patients with CIS. First, the level of miR-221 in the peripheral blood of patients with CIS and in healthy volunteers was detected using RT-qPCR. Results indicated that compared with the healthy volunteers, the level of miR-221 in the peripheral blood of patients with CIS significantly decreased (P<0.01; Fig. 1), indicating the important role of miR-221 in CIS.

PTEN is a direct target of miR-221. miRNA target site prediction software (microRNA.org) was used to identify the binding sites between miR-221 and the 3'-UTR of PTEN mRNA (Fig. 2A). The dual-luciferase reporter assay results indicated that compared with HUVECs co-transfected with mimic control and WT-PTEN, the luciferase activity of HUVECs co-transfected with miR-221 mimic and WT-PTEN was significantly reduced (P<0.01; Fig. 2B). However, compared with HUVECs co-transfected with mimic control and MUT-PTEN, there was no significant difference in the luciferase activity of HUVECs co-transfected with miR-221 mimic and MUT-PTEN (Fig. 2B). These results indicated that PTEN was a direct target of miR-221 in HUVECs.

miR-221 downregulation inhibits the function of HUVECs. The effect of miR-221 downregulation on HUVECs was investigated using miR-221 inhibitor. Transfection with miR-221 inhibitor for 48 h significantly decreased the level of miR-221 in HUVECs (P<0.01; Fig. 3A). Further analysis indicated that compared with the inhibitor control, miR-221 inhibitor significantly decreased the cell viability (P<0.05; Fig. 3B), migration (P<0.05; Fig. 3C) and invasion ability (P<0.05; Fig. 3D) of HUVECs. Inhibition of miR-221 also induced cell apoptosis compared with the inhibitor control (P<0.01; Fig. 3E and F). The protein level of Bcl-2 was decreased by miR-221 inhibitor, while Bax protein expression was markedly enhanced in miR-221 inhibitor-transfected HUVECs compared with inhibitor control (Fig. 3G). To investigate the effect of miR-221 on the angiogenic abilities of endothelial cells, the tube formation of HUVECs was examined with findings demonstrating that miR-221 inhibitor repressed tube formation of HUVECs compared with the inhibitor control. (P<0.01; Fig. 3H).
miR-221 upregulation promotes the function of HUVECs. The effect of miR-221 upregulation on HUVECs was also investigated in the present study. HUVECs were transfected with control-plasmid, PTEN-plasmid, miR-221 mimic, miR-221 mimic + control-plasmid, or miR-221 mimic + PTEN-plasmid for 48 h. miR-221 mimic significantly increased the level of PTEN in HUVECs compared with the mimic control group (P<0.01; Fig. 4A). PTEN-plasmid significantly enhanced the mRNA level of PTEN in HUVECs compared with the control-plasmid group (P<0.01; Fig. 4B). Compared with the mimic control group, miR-221 mimic significantly increased the cell viability (P<0.05; Fig. 4C), migration (P<0.05; Fig. 4D) and invasion ability (P<0.05; Fig. 4E) of HUVECs, and reduced cell apoptosis (P<0.01; Fig. 4F). In addition, miR-221 mimic markedly enhanced the protein level of Bcl-2 and inhibited Bax protein expression in HUVECs (Fig. 4G). In addition, miR-221 mimic significantly promoted the tube formation of HUVECs compared with the mimic control (P<0.01; Fig. 4H). More importantly, all the effects of miR-221 mimic on HUVECs were reversed by PTEN overexpression (Fig. 4).

Effect of miR-221 on PTEN/PI3K/AKT pathway in HUVECs. Finally, the effect of miR-221 on PTEN/PI3K/AKT pathway was investigated. The results suggested that miR-221 mimic markedly inhibited PTEN protein expression and enhanced the level of AKT phosphorylation (Fig. 5A) compared with the mimic control group. Transfection with the miR-221 mimic significantly enhanced the ratio of p-AKT/AKT (Fig. 5B) compared with the mimic control group, in addition to significantly increasing the levels PTEN mRNA expression compared with the mimic control group (Fig. 5C). All the effects of miR-221 mimic on the expression of PTEN and p-AKT were reversed by PTEN overexpression (P<0.01; Fig. 5).

Discussion

The present study demonstrated that miR-221 was significantly downregulated in patients with CIS. Downregulation of miR-221 significantly inhibited the function of HUVECs as evidenced by the decreased cell viability, migration and invasion ability and tube formation with increased cell apoptosis. By contrast, miR-221 upregulation promoted cell viability, migration, invasion and tube formation of HUVECs and reduced cell apoptosis. In addition, miR-221 upregulation significantly inhibited PTEN expression and enhanced the phosphorylation of AKT in HUVECs. All the effects of miR-221 upregulation on HUVECs were eliminated by PTEN overexpression. The present findings indicated that miR-221 promoted the function of HUVECs and angiogenesis. Therefore, miR-221 might be a novel treatment target for CIS.

Currently, CIS seriously endangers human life and health (1,2). CIS recovery is a complex process, including inhibition of apoptosis, neuroinflammation, neurogenesis and angiogenesis (30,31). The angiogenic process of endothelial cells is critical for new blood vessel formation and blood flow recovery (9). In recent years, research on miRNA and angiogenesis in CIS has received increasing attention (16,32,33). miR-221, which belongs to the miR-21/22 cluster (34,35), has been well studied in a variety of cancers including hepatocellular carcinoma, prostate adenocarcinoma and colorectal carcinoma (21-22). miR-221 has also been identified to have an important role in tumor angiogenesis (24). Tsai et al (25) reported that miR-221 is significantly decreased in the serum of stroke patients and there is a 10.4-fold increase of stroke risk when miR-221 levels decrease. miR-221 has also been found to be downregulated in the cerebrospinal fluid of patients with CIS (26).

In the present study, consistent with the literature (25,26), it was identified that, the level of miR-221 in the peripheral blood of patients with CIS significantly decreased compared with the healthy volunteers, indicating that miR-221 may serve a role during CIS. Consistent with previous studies (36-38), PTEN was confirmed to be a direct target of miR-221. PTEN is a dual lipid/protein phosphatase that has key roles in cell growth, migration and angiogenesis (39-41). However, contrary to the present results, Urbich et al (42) determined that miR-221 inhibits endothelial cell activity in vitro through indirectly
Figure 3. Effect of miR-221 inhibitor on HUVECs. (A) HUVECs were transfected with inhibitor control or miR-221 inhibitor for 48 h then, the level of miR-221 in HUVECs was detected using reverse transcription-quantitative PCR. (B) Cell viability was measured by an MTT assay. (C) Cell migration and (D) invasion were determined using Transwell and Matrigel assays, respectively. (E) Representative flow cytometry plots and (F) quantification of cell apoptosis was measured using flow cytometry. (G) Protein level of Bax and Bcl-2 was detected by western blot analysis. (H) Tube formation assay was used to determine cell tube formation ability. Data are presented as the mean ± standard deviation. *P<0.05, **P<0.01 vs. inhibitor control. miR, microRNA; HUVECs, human umbilical vein endothelial cells; PI, propidium iodide; FITC, fluorescein isothiocyanate.
The reason for this discrepancy requires further research to elucidate the mechanisms. PTEN regulates the PI3K signaling pathway (40). A previous study revealed that human aortic smooth muscle cell-derived exosomes of miR-221 inhibit autophagy in HUVECs by modulating the PTEN/Akt signaling pathway (43). Therefore, to explore the mechanism by which miR-221 functioned on HUVECs, the effect of miR-221 on the PTEN/PI3K/AKT pathway was investigated in the present study. It was determined that miR-221 upregulation significantly inhibited the expression of PTEN in HUVECs, and as expected, the phosphorylation of AKT was significantly enhanced. All the effects of miR-221 mimic on HUVECs were reversed by PTEN overexpression.
This is only a preliminary study of the role of miR-221 in CIS therefore, further in-depth research should be performed to confirm its role. For example, the role of PTEN in angiogenesis should be investigated. The correlation between the expression levels of miR-221 and PTEN and the clinicopathological parameters of CIS patients needs to be explored. Finally, the function of miR-221 in CIS should be investigated in vivo. Future work will focus on these research areas.

In summary, the present study verified that miR‑221 expression was downregulated in CIS patients (25,26). However, to the best of our knowledge, the present study was the first to demonstrate that miR-221 promoted the function of HUVECs by regulating the PTEN/PI3K/AKT pathway, thus promoting angiogenesis. Therefore, miR-221 might be a promising and novel therapeutic target for CIS treatment.

Acknowledgements

Not applicable.

Funding

The present study was supported by the National Science Foundation of China (grant no. H0928).

Availability of data and materials

The analyzed data sets generated during the present study are available from the corresponding author on reasonable request.

Authors’ contributions

HP designed the current study, collected and analyzed the data, performed statistical analysis, searched the literature, and prepared the manuscript. HY and XX contributed to data collection and data interpretation. SHL contributed to statistical analyzes and interpreted the data. All authors read and approved the final manuscript.

Ethics approval and consent to participate

This study was approved by the Ethical Committee of the Affiliated Hospital of Guizhou Medical University, and written informed consent was obtained from by each patient.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Middleton LE, Corbett D, Brooks D, Sage MD, Macintosh BJ, McIlroy WE and Black SE: Physical activity in the prevention of ischemic stroke and improvement of outcomes: A narrative review. Neurosci Biobehav Rev 37: 133-137, 2013.

2. Doyle KP, Simon RP and Stenzel-Poore MP: Neuropharmacology-special issue on cerebral ischemia mechanisms of ischemic brain damage-review article. Neuropharmacology 55: 310-318, 2008.
and κ and...  

25. Tsai PC, Liao YC, Wang YS, Lin HF, Lin RT and Jao SH: Serum microRNA-21 and microRNA-221 as potential biomarkers for cerebrovascular disease. J Vasc Res 50: 346-354, 2013.

26. Sørensen SS, Nygaard AB, Nielsen MY, Jensen K and Christensen T: miRNA expression profiles in cerebrospinal fluid and blood of patients with acute ischemic stroke. Transl Stroke Res 6: 711-718, 2017.

27. Heldner MR, Zuberl C, Mattle HP, Schroth G, Weck A, Monu ML, Gralla J, Jung S, El-Koussy M, Lüdi R, et al: National Institutes of Health stroke scale score and vessel occlusion in 2152 patients with acute ischemic stroke. Stroke 44: 1153-1157, 2013.

28. Powierski B, Rabinstein AA, Ackerson T, Adedeji OM, Bambakidis NC, Becker K, Biller J, Brown M, Delschaft BW, Hoh B, et al: 2018 Guidelines for the early management of patients with acute ischemic stroke: A guideline for healthcare professionals from the American heart association/American stroke association. Stroke 49: e46-e110, 2018.

29. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25: 402-408, 2001.

30. Attanasio S and Schaar G: Therapeutic angiogenesis for the management of refractory angina: Current concepts. Cardiovasc Ther 29: e1-e11, 2011.

31. Chopp M, Zhang ZG and Jiang Q: Neurogenesis, angiogenesis, and MRI indices of functional recovery from stroke. Stroke 38 (Suppl 2): S827-S831, 2007.

32. Yuanc N, Zhang Z and Liu J: MiRNA-27b regulates angiogenesis by targeting ampk in mouse ischemic stroke model. Cell Biol Int 36: 354-366, 2012.

33. Yin KJ, Hamblin M and Chen YE: Angiogenesis-regulating microRNAs and ischemic stroke. Curr Vasc Pharmacol 13: 352-365, 2015.

34. Chen WX, Hu Q, Qiu MT, Zhong SL, Xu JJ, Tang JH and Zhao JH: miR-221/222: Promising biomarkers for breast cancer. Tumour Biol 34: 1361-1370, 2013.

35. Liu S, Sun X, Wang M, Hou Y, Zhan Y, Jiang Y, Liu Z, Cao X, Chen P, Liu Z, et al: A microRNA 221-and 222-mediated feedback loop maintains constitutive activation of NFkB and STAT3 in colorectal cancer cells. Gastroenterology 147: 847-859, 2014.

36. Gong ZH, Zhou F, Shi C, Xiang T, Zhou CK, Wang QQ, Jiang YS and Gao SF: miRNA-221 promotes cutaneous squamous cell carcinoma progression by targeting PTEN. Cell Mol Biol Lett 24: 9, 2019.

37. Ren Y, Yang M, Ma R, Gong Y, Zou Y, Wang Y and Wu J: Microcytisin-LR promotes migration via the cooperation between microRNA-221/PTEN and STAT3 signal pathway in colon cancer cell line DLD-1. Ecotoxicol Environ Saf 167: 107-113, 2019.